Interleukin-1 Blockade for the Treatment of Heart Failure in Patients With Advanced Chronic Kidney Disease
Status:
Withdrawn
Trial end date:
2019-05-15
Target enrollment:
Participant gender:
Summary
Interleukin-1 blockade for the treatment of heart failure in patients with advanced chronic
kidney disease (End-stage renal disease and Heart fAilure - Anakinra Remodeling Trial) is a
Phase 2, single-arm trial designed to estimate the effect of anakinra, a recombinant human
Interleukin-1 (IL-1) receptor antagonist, on cardiorespiratory fitness in patients with
advanced chronic kidney disease and heart failure.